Shanghai HeartCare Medical Technology Corporation Ltd. has announced a proposal for the adoption of the 2025 H Share Incentive Scheme. This scheme includes H share awards aimed at aligning the interests of eligible participants with the long-term performance of the company. The adoption of this scheme is subject to approval by the shareholders at a general meeting. The Board, including independent non-executive directors, believes the scheme's terms are fair, reasonable, and in the best interest of the company and its shareholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.